Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8970030 | 0.81 | CTSD (0.50) | CTSDLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8969534 | 0.80 | TGFBR1 (0.31) | — | |
| SCHEMBL8969623 | 0.77 | HTR2C (0.36) | CTSDLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8968760 | 0.75 | PDE3B (0.34) | PDE3BPDE3A | |
| SCHEMBL8969282 | 0.73 | CTSD (0.34) | CTSDLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8969508 | 0.73 | PDE3B (0.33) | CTSDLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8969270 | 0.69 | — | — | |
| SCHEMBL8970250 | 0.69 | HTR2C (0.32) | — | |
| SCHEMBL8969218 | 0.68 | OPRM1 (0.31) | — | |
| SCHEMBL8968884 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5486512-A | LEARNING ENHANCEMENT | WARNER-LAMBERT COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1993003034-A1 | QUINAZOLINE DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-02-18 | — | — | WO | disclosed |